🔗 Share this article

As the United States continues making historic changes to its vaccination recommendations, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on COVID-19 shots during the pandemic and has focused upon possible fatalities after Covid vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Schedule

Health officials had intended to reveal radical revisions to the childhood vaccine schedule earlier this month, aligning the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US at odds with many the international standard with insufficient data for benefit. The planned update has been postponed until the next year.

Rather than Vinay Prasad, Dr. Høeg is set to present at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a greater focus upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending certain childhood immunization guidelines in the US so as to align more similar to the Danish model, a society with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

So far public appearances, she has continued to focus on immunizations – typically the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Qualifications

The appointee has little discernible track record in medication creation, oversight or management, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in managing a sizeable institution. She lacks background in drug approvals.”

Previous directors of the center would “understand laws and regulations and the science of medication creation”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that former directors who led the center have had.”

The drug center has an immense portfolio at the FDA, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the generic drug division clears a multitude of generic drugs. There is also a biosimilars program, OTC medication office and so forth, and every single one have to be managed,” she said. “The thing you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative aspect to the role, which oversees over 5,000 staff members. “It is a huge administrative position, if you do it right,” Woodcock concluded.

Official Statement and Disputed Programs

When asked about inquiries about Dr. Høeg's credentials and whether this selection signifies more teamwork among FDA leaders on vaccines, a press secretary stated that the “concerns rely on incorrect presumptions”.

“This background is consistent with the responsibilities of her role,” the official stated, pointing to the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg inherits the agency head's new priority voucher program, a contentious one-day medication authorization process that apparently worried her preceding directors. “By what process are these therapies being selected for this fast-track system? Who is making the decisions?” Howard said. “There is a lot of confidentiality going on at the agency right now.”

In general, he remarked, “the agency seems to be moving towards less stringent regulations of most medications, aside from immunizations.”

Public Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if troubling, past, Howard have noted. She published a study using unconfirmed public submissions to determine the rate of myocarditis after COVID-19 immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the incoming federal leadership encompassed changing guidelines for novel immunizations and ending “unnecessary” immunizations, she said post-election on a online show. At the FDA, Dr. Høeg has allegedly proposed preventing adolescent males from receiving Covid vaccines.

“She is an thorough dogmatist who begins with her beliefs and reverse-engineers to accommodate the evidence in a extremely misleading, untruthful way,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|